Panacea Venture

Panacea Venture is an active global life sciences venture capital firm spun out from Kleiner Perkins in 2017. It specializes in investing in and incubating early-stage healthcare and biotech companies with disruptive technologies. The fund has raised three USD funds from institutional and strategic investors and has invested in over thirty private companies as well as several public ones. Its investment focus spans therapeutics—including small molecules, biologics, cell/gene therapies—diagnostics, medical devices, CROs/CDMOs/CMOs. About one-third of its investments are company formations or incubations led by the fund’s team. Portfolio highlights include next-generation immunotherapies (e.g., CAR-T), gene editing platforms/base editors for rare diseases or cancer therapies, exosome therapeutics for regenerative medicine or delivery technologies for biologics/small molecules.